Research Article
The Interplay between Zinc, Vitamin D and, IL-17 in Patients with Chronic Hepatitis C Liver Disease
Table 1
Demographical and clinical characteristic of patients and controls.
| | Clinical characteristics | All patients | Recently diagnosed | Compensated | Decompensated | Controls |
| | Age, median (range) | 48 (22–76) | 30 (22–35) | 48 (40–54) | 63 (53–76) | 31 (27–40) | | Sex (M/F) | 35/35 | 9/7 | 17/20 | 9/8 | 22/28 | | Albumin (g/dL), median (IQR) | 3.6 (2.4–4) | 4.2 (4–4.4) | 3.6 (3.5–3.8) | 2.3 (1.95–2.45) | >4.1 | | Total Bilirubin (mg/dL), median (IQR) | 0.9 (0.7–1.7) | 0.7 (0.5–0.8) | 0.7 (0.6–0.9) | 3.14 (1.7–5.1) | <1.2 | | Direct Bilirubin (mg/dL), median (IQR) | 0.3 (0.2–0.9) | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | 1.07 (0.8–2.35) | <0.2 | | P.T# (sec), median (IQR) | 13 (11.8–16.6) | 11.9 (11.63–12.48) | 12.5 (11.8–13) | 17.4 (16.3–19.9) | <12 | | INR, median (IQR) | 1.015 (0.98–1.5) | 0.99 (0.9–1.04) | 1 (0.9–1.07) | 1.5 (1.48–1.7) | 0.93 (0.9–1.02) | | ALT (IU/L), Mean ± SD | 53.84 ± 12.36 | 56.5 ± 13 | 47.59 ± 11.87 | 58 ± 10.22 | 15.5 ± 7.65 | | AST (IU/L), Mean ± SD | 42.74 ± 10.59 | 47.44 ± 8.78 | 38.35 ± 9.32 | 42.71 ± 11.93 | 15.5 ± 6.25 | | PCR (IU/mL), median (IQR) | 31850 (22100–599000) | 27600 (22100–646000) | 36100 (22100–599000) | 27600 (21200–630000) | — | | IL-17 (pg/mL), Mean ± SD | 776.3 ± 57.39 | 295.8 ± 48.04 | 766.1 ± 62.90 | 1207 ± 113.8 | 72.17 ± 4.622 | | ZN (g/dL), Mean ± SD | 59.01 ± 1.86 | 72.81 ± 2.679 | 58.13 ± 2.445 | 48.00 ± 2.727 | 91.28 ± 1.838 | | Vit. D (ng/mL), Mean ± SDa | — | — | 18.65 ± 12.89 | — | 55.8 ± 16.27 |
|
|
aData available for 20 patients.
P.T: prothrombin time; INR: international normalized ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; IQR: the interquartile range; HCV: hepatitis C virus.
|
